This is the first prospective study to evaluate epigenetic mechanisms of PTPRG regulation amongst CML patient's population where the rate of IM resistances is higher than other reported parts of the world (Al‐Dewik, Ayoubi et al., 2011; Al‐Dewik et al., 2014; Al‐Dewik, Jewell et al., 2014; Al‐Dewik, Morsi et al., 2016; Patel et al., 2017). The gene discussed is PTPRG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.